Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials | Zendy

B. Clotet | Zendy; Nathan Clumeck | Zendy; Christine Katlama | Zendy; Steven Nijs | Zendy; James Witek | Zendy

Open Access

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials

Author(s) -

B. Clotet,

Nathan Clumeck,

Christine Katlama,

Steven Nijs,

James Witek

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq332

Subject(s) - etravirine , virology , medicine , coinfection , human immunodeficiency virus (hiv) , hepatitis c virus , virus , viral load , antiretroviral therapy

Human immunodeficiency virus (HIV)-infected patients are frequently co-infected with hepatitis B and/or C virus (HBV/HCV). The safety of etravirine was investigated over 96 weeks in patients co-infected with HIV type-1 (HIV-1) and HBV and/or HCV in the Phase III DUET trials. DUET-1 and DUET-2 are registered with clinicaltrials.gov (NCT00254046 and NCT00255099, respectively).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research